Effrosyni Birbas

Dr. Effrosyni Birbas

Feinstein Institute for Medical Research, Manhasset, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
Athena DavriAthena Davri
Athena Davri
Effrosyni BirbasEffrosyni Birbas
Effrosyni Birbas
Theofilos KanavosTheofilos Kanavos
Theofilos Kanavos
GNGeorgios Ntritsos
Georgios Ntritsos
Nikolaos GiannakeasNikolaos Giannakeas
Nikolaos Giannakeas
ABAnna Batistatou
Anna Batistatou
Colorectal cancer (CRC) is the second most common cancer in women and the third most common in men, with an increasing incidence. Pathology diagnosis complemented with prognostic and predictive biomarker information is the first step for personalized treatment. The increased diagnostic load in the pathology laboratory, combined with the reported intra- and inter-variability in the assessment of biomarkers, has prompted the quest for reliable machine-based methods to be incorporated into the routine practice. Recently, Artificial Intelligence (AI) has made significant progress in the medical field, showing potential for clinical applications. Herein, we aim to systematically review the current research on AI in CRC image analysis. In histopathology, algorithms based on Deep Learning (DL) have the potential to assist in diagnosis, predict clinically relevant molecular phenotypes and microsatellite instability, identify histological features related to prognosis and correlated to metastasis, and assess the specific components of the tumor microenvironment.

13 December 2023 in BMC Medicine
Verified
Journal Article
Open access
PDF file
IMIoannis Mitrogiannis
Ioannis Mitrogiannis
EEEvangelos Evangelou
Evangelos Evangelou
AEAthina Efthymiou
Athina Efthymiou
TKTheofilos Kanavos
Theofilos Kanavos
Effrosyni BirbasEffrosyni Birbas
Effrosyni Birbas
SPStefania Papatheodorou
Stefania Papatheodorou
Background: Preterm birth defined as delivery before 37 gestational weeks is a leading cause of neonatal and infant morbidity and mortality. The aim of this study is to summarize the evidence from meta-analyses of observational studies on risk factors associated with PTB, evaluate whether there are indications of biases in this literature, and identify which of the previously reported associations are supported by robust evidence.Methods: We searched PubMed and Scopus until February 2021, in order to identify meta-analyses examining associations between risk factors and PTB. For each meta-analysis, we estimated the summary effect size, the 95% confidence interval, the 95% prediction interval, the between-study heterogeneity, evidence of small-study effects, and evidence of excess-significance bias. Evidence was graded as robust, highly suggestive, suggestive, and weak.Results: Eighty-five eligible meta-analyses were identified, which included 1480 primary studies providing data on 166 associations, covering a wide range of comorbid diseases, obstetric and medical history, drugs, exposure to environmental agents, infections, and vaccines. Ninety-nine (59.3%) associations were significant atP < 0.05, while 41 (24.7%) were significant atP < 10−6. Ninety-one (54.8%) associations had large or very large heterogeneity. Evidence for small-study effects and excess significance bias was found in 37 (22.3%) and 12 (7.2%) associations, respectively. We evaluated all associations according to prespecified criteria. Seven risk factors provided robust evidence: amphetamine exposure, isolated single umbilical artery, maternal personality disorder, sleep-disordered breathing (SDB), prior induced termination of pregnancy with vacuum aspiration (I-TOP with VA), low gestational weight gain (GWG), and interpregnancy interval (IPI) following miscarriage < 6 months.Conclusions: The results from the synthesis of observational studies suggest that seven risk factors for PTB are supported by robust evidence. Routine screening for sleep quality and mental health is currently lacking from prenatal visits and should be introduced. This assessment can promote the development and training of prediction models using robust risk factors that could improve risk stratification and guide cost-effective preventive strategies.Trial registration: PROSPERO 2021 CRD42021227296.

5 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Athena DavriAthena Davri
Athena Davri
Effrosyni BirbasEffrosyni Birbas
Effrosyni Birbas
Theofilos KanavosTheofilos Kanavos
Theofilos Kanavos
GNGeorgios Ntritsos
Georgios Ntritsos
Nikolaos GiannakeasNikolaos Giannakeas
Nikolaos Giannakeas
ABAnna Batistatou
Anna Batistatou
Lung cancer is one of the deadliest cancers worldwide, with a high incidence rate, especially in tobacco smokers. Lung cancer accurate diagnosis is based on distinct histological patterns combined with molecular data for personalized treatment. Precise lung cancer classification from a single H&E slide can be challenging for a pathologist, requiring most of the time additional histochemical and special immunohistochemical stains for the final pathology report. According to WHO, small biopsy and cytology specimens are the available materials for about 70% of lung cancer patients with advanced-stage unresectable disease. Thus, the limited available diagnostic material necessitates its optimal management and processing for the completion of diagnosis and predictive testing according to the published guidelines. During the new era of Digital Pathology, Deep Learning offers the potential for lung cancer interpretation to assist pathologists’ routine practice. Herein, we systematically review the current Artificial Intelligence-based approaches using histological and cytological images of lung cancer. Most of the published literature centered on the distinction between lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung carcinoma, reflecting the realistic pathologist’s routine. Furthermore, several studies developed algorithms for lung adenocarcinoma predominant architectural pattern determination, prognosis prediction, mutational status characterization, and PD-L1 expression status estimation.

27 June 2023 in Children
Verified
Journal Article
Open access
PDF file
Effrosyni BirbasEffrosyni Birbas
Effrosyni Birbas
Theofilos KanavosTheofilos Kanavos
Theofilos Kanavos
FGFani Gkrozou
Fani Gkrozou
CSCharikleia Skentou
Charikleia Skentou
ANGELOS DANIILIDISANGELOS DANIILIDIS
ANGELOS DANIILIDIS
AVANASTASIA VATOPOULOU
ANASTASIA VATOPOULOU
Most abdominal masses in the pediatric population derive from the ovaries. Ovarian masses can occur in all ages, although their incidence, clinical presentation and histological distribution vary among different age groups. Children and adolescents may develop non-neoplastic ovarian lesions, such as functional cysts, endometrioma, torsion, abscess and lymphangioma as well as neoplasms, which are divided into germ cell, epithelial, sex-cord stromal and miscellaneous tumors. Germ cell tumors account for the majority of ovarian neoplasms in the pediatric population, while adults most frequently present with epithelial tumors. Mature teratoma is the most common ovarian neoplasm in children and adolescents, whereas dysgerminoma constitutes the most frequent ovarian malignancy. Clinical manifestations generally include abdominal pain, palpable mass, nausea/vomiting and endocrine alterations, such as menstrual abnormalities, precocious puberty and virilization. During the investigation of pediatric ovarian masses, the most important objective is to evaluate the likelihood of malignancy since the management of benign and malignant lesions is fundamentally different. The presence of solid components, large size and heterogenous appearance on transabdominal ultrasonography, magnetic resonance imaging and computed tomography indicate an increased risk of malignancy. Useful tumor markers that raise concern for ovarian cancer in children and adolescents include alpha-fetoprotein, lactate dehydrogenase, beta subunit of human chorionic gonadotropin, cancer antigen 125 and inhibin. However, their serum levels can neither confirm nor exclude malignancy. Management of pediatric ovarian masses needs to be curative and, when feasible, function-preserving and minimally invasive. Children and adolescents with an ovarian mass should be treated in specialized centers to avoid unnecessary oophorectomies and ensure the best possible outcome.

2 March 2023 in Diseases
Verified
Journal Article
Open access
PDF file
Theofilos KanavosTheofilos Kanavos
Theofilos Kanavos
Effrosyni BirbasEffrosyni Birbas
Effrosyni Birbas
APAlexanndra Papoudou-Bai
Alexanndra Papoudou-Bai
Eleftheria HatzimichaelEleftheria Hatzimichael
Eleftheria Hatzimichael
AKAikaterini Kitsouli
Aikaterini Kitsouli
PKPanagiotis Kanavaros
Panagiotis Kanavaros
Primary bone lymphoma (PBL) is a rare neoplasm of malignant lymphoid cells presenting with one or more bone lesions without nodal or other extranodal involvement. It accounts for approximately 1% of all lymphomas and 7% of malignant primary bone tumors. Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) represents the predominant histological type and constitutes over 80% of all cases. PBL may occur at all ages with a typical diagnosis age of 45–60 years and a slight male predominance. Local bone pain, soft tissue edema, palpable mass and pathological fracture are the most common clinical features. Diagnosis of the disease, which is frequently delayed due to its non-specific clinical presentation, is based on the combination of clinical examination and imaging studies and confirmed by combined histopathological and immunohistochemical examination. PBL can develop in any part of the skeleton, although it occurs most commonly in the femur, humerus, tibia, spine and pelvis. The imaging appearance of PBL is highly variable and unspecific. In terms of the cell-of-origin, most cases of primary bone DLBCL (PB-DLBCL), NOS belong to the germinal center B-cell-like subtype and specifically originate from germinal center centrocytes. PB-DLBCL, NOS has been considered a distinct clinical entity based on its particular prognosis, histogenesis, gene expression and mutational profile and miRNA signature. PBL carries a favorable prognosis, especially when treated with combined chemoradiotherapy.

31 October 2024 in Hormones
Verified
Journal Article
Closed access
PDF file
Effrosyni BirbasEffrosyni Birbas
Effrosyni Birbas
AVANASTASIA VATOPOULOU
ANASTASIA VATOPOULOU
Theofilos KanavosTheofilos Kanavos
Theofilos Kanavos
KBKyriakos Birmpas
Kyriakos Birmpas
CSChara Skentou
Chara Skentou
FGFani Gkrozou
Fani Gkrozou